# Expanding the Genetic Code with Lysine Aminoacylation

**Authors:** Xinyu Li, Qinglei Gan, Chenguang Fan

PMC · DOI: 10.1021/jacs.6c03157 · Journal of the American Chemical Society · 2026-03-16

## TL;DR

This study expands the genetic code to create tools for studying lysine aminoacylation and shows how it affects metabolic enzymes in human cells.

## Contribution

The development of orthogonal translation systems for ten types of lysine aminoacylation in bacterial and mammalian cells.

## Key findings

- Lysine valylation and tyrosylation impair pyruvate kinase and glucose-6-phosphate dehydrogenase activities.
- Lysine valylation of pyruvate kinase decreases the basal glycolytic rate in living human cells.

## Abstract

Lysine aminoacylation
is a newly discovered protein post-translational
modification that is found in humans. However, few studies have been
implemented to further investigate its function, possibly due to limited
tools to produce target proteins with homogeneously aminoacylated
lysine residues at specific sites. To achieve this goal, we applied
the genetic code expansion strategy, engineered pyrrolysyl-tRNA synthetase,
and established orthogonal translation systems for ten types of lysine
aminoacylation compatible for both bacterial and mammalian cells.
Because metabolic enzymes are preferred substrate proteins of lysine
aminoacylation, we tested the effect of lysine aminoacylation on metabolic
enzymes and demonstrated that lysine valylation and tyrosylation impaired
pyruvate kinase and glucose-6-phosphate dehydrogenase activities,
respectively. Further in vivo studies showed that
lysine valylation of pyruvate kinase decreased the basal glycolytic
rate in living human cells. In summary, this work provides a toolbox
to study lysine aminoacylation.

## Linked entities

- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** WARS1 (tryptophanyl-tRNA synthetase 1) [NCBI Gene 7453] {aka GAMMA-2, HMN9, HMND9, IFI53, IFP53, NEDMSBA}, MAP3K5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 4217] {aka ASK1, MAPKKK5, MEKK5}, LARS1 (leucyl-tRNA synthetase 1) [NCBI Gene 51520] {aka HSPC192, ILFS1, LARS, LEURS, LEUS, LFIS}, MARS1 (methionyl-tRNA synthetase 1) [NCBI Gene 4141] {aka CMT2U, ILFS2, ILLD, MARS, METRS, MRS}, QARS1 (glutaminyl-tRNA synthetase 1) [NCBI Gene 5859] {aka GLNRS, MSCCA, PRO2195, QARS}, AARS1 (alanyl-tRNA synthetase 1) [NCBI Gene 16] {aka AARS, CMT2N, DEE29, EIEE29, HDLS2, TTD8}, CcdB [NCBI Gene 6276084], KARS1 (lysyl-tRNA synthetase 1) [NCBI Gene 3735] {aka CMTRIB, DEAPLE, DFNB89, KARS, KARS2, KRS}, AURKA (aurora kinase A) [NCBI Gene 6790] {aka AIK, ARK1, AURA, BTAK, PPP1R47, STK15}, TARS1 (threonyl-tRNA synthetase 1) [NCBI Gene 6897] {aka TARS, TTD7, ThrRS}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, DARS1 (aspartyl-tRNA synthetase 1) [NCBI Gene 1615] {aka DARS, HBSL, aspRS}, WARS2 (tryptophanyl tRNA synthetase 2, mitochondrial) [NCBI Gene 10352] {aka NEMMLAS, PKDYS3, TrpRS, mtTrpRS}, RRAGA (Ras related GTP binding A) [NCBI Gene 10670] {aka FIP-1, FIP1, RAGA}, chloramphenicol acetyltransferase [NCBI Gene 8319152], DARS2 (aspartyl-tRNA synthetase 2, mitochondrial) [NCBI Gene 55157] {aka ASPRS, CMT2LL, LBSL, MT-ASPRS, mtAspRS}, CAT [NCBI Gene 2847485], TRNG (tRNA-Gly) [NCBI Gene 4563] {aka MTTG}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}
- **Diseases:** cancer (MESH:D009369), toxicity (MESH:D064420), liver cancer (MESH:D006528)
- **Chemicals:** CH3CN (MESH:C032159), proton (MESH:D011522), TGS (MESH:C026285), Lysine (MESH:D008239), TBS (MESH:D013725), SOC (MESH:C001599), Val (MESH:D014633), penicillin (MESH:D010406), Glu (MESH:D018698), PBS (MESH:D007854), AA (MESH:D000596), Cys (MESH:D003545), His6 (MESH:C471213), pyrrolysine (MESH:C456839), Sinapic acid (MESH:C073734), pyruvate (MESH:D019289), HCl (MESH:D006851), ATP (MESH:D000255), tetrazolium salt (MESH:D013778), carbohydrate (MESH:D002241), CO2 (MESH:D002245), Tween 20 (MESH:D011136), MTT (MESH:C070243), antimycin A (MESH:D000968), Tyr (MESH:D014443), NaCl (MESH:D012965), glucose (MESH:D005947), formic acid (MESH:C030544), Nicotinamide (MESH:D009536), CAS #: (MESH:D002118), PVDF (MESH:C024865), streptomycin (MESH:D013307), 2-DG (MESH:D003847), agarose (MESH:D012685), Bio-Safe Coomassie stain (-), imidazole (MESH:C029899), lactate (MESH:D019344), Met (MESH:D008715), oxygen (MESH:D010100), Thr (MESH:D013912), Gln (MESH:D005973), acid (MESH:D000143), IPTG (MESH:D007544), chloramphenicol (MESH:D002701), KCl (MESH:D011189), SDS (MESH:D012967), arabinose (MESH:D001089), ADP (MESH:D000244), K (MESH:D011188), lipids (MESH:D008055), pentose phosphate (MESH:D010428), Rotenone (MESH:D012402), NADP+ (MESH:D009249), Trp (MESH:D014364)
- **Species:** Pseudomonas aeruginosa (species) [taxon 287], Methanomethylophilus alvi (species) [taxon 1291540], Escherichia coli (E. coli, species) [taxon 562], Methanosarcina mazei (species) [taxon 2209], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** H62Y, V168A, V42I, A100E, Lys at position 403, K62, T75, Gln at position 62, V31I, Gln at position 403, Y349F, T56P, K181E, A190V, V168, V75I
- **Cell lines:** TOP10 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TT29), E. coli — Mus musculus (Mouse), Hybridoma (CVCL_C5CR), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), BL21 (DE3) — Mus musculus (Mouse), Hybridoma (CVCL_B7HM), 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13022859/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13022859/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC13022859/full.md

---
Source: https://tomesphere.com/paper/PMC13022859